- CA$36.12m
- CA$85.74m
- CA$28.74m
Canada's LSL Pharma Q2 revenue surges on acquisition boost, eye-drop launches
Brief: Lsl Pharma Group Reports Record Revenues And Second Quarter 2026 Results
Brief: LSL Pharma Group Successfully Obtained U.S. FDA Certification For The Manufacturing Of Ophthalmic Ointments For Commercialization In The United States
Brief: LSL Pharma Group Announces Closing Of The Acquisition Of Juno Otc And Final $2M Closing Of Upsized $12M Offering
Brief: Lsl Pharma Group Announces Acquisition Of Juno Otc
Brief: Lsl Pharma Group Secures $17.5 Million From Desjardins And Bdc
Brief: LSL Pharma Group Reports Record Revenues And First Quarter 2025 Results
Brief: LSL Pharma Group Announces The Signing Of Two Agreements To Market New Ophthalmic Products In Canada
Brief: LSL Pharma Group Appoints Louis Laflamme To The Board Of Directors
Brief: Lsl Pharma Group Expands Its Activities By Aquiring Dermolab Pharma
Brief: LSL Pharma Group Completes the Acquisition of Virage Santé
Brief: LSL Pharma Announces Combination Of Private Placements For Maximum Aggregate Gross Proceeds of $4.5 Mln
Brief: LSL Pharma Group Announces Listing Of Convertible Redeemable Debentures On The TSXV
Brief: LSL Pharma Group Announces Upsizing Of Its Private Placement From $3.5 Mln To $7.5 Mln
Brief: Lsl Pharma Group Secures $6.44 Million As The First Closing Of Concurrent Non-Brokered Private Placements
Brief: LSL Pharma Group Announces An Extension Of Its Convertible Debentures Offering
Brief: LSL Pharma Group Appoints Luc Mainville As Chief Financial Officer
Brief: LSL Pharma Q3 Revenue CAD 2.512 Mln
Brief: LSL Pharma Announces Exclusive Distribution Agreement With Fera Pharmaceuticals To Alleviate Drug Shortage In U.S. Hospitals